In mouse tumor models, we could show that Adam2 expression is induced in KrasG12D but not BrafV600E tumors and its expression is further increased upon immunotherapy, indicating that Adam2 is an oncogene- and immune-responsive bona fide cancer-testis antigen. Here, ADAM2 is linked to cancer.